

### TNF-R-II / TNFR2 (mouse) Antibody (internal region)

Peptide-affinity purified goat antibody Catalog # AF3597a

### **Specification**

### TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Product Information

Application WB

Primary Accession P25119.1

Other Accession NP 035740.2, 21938 (mouse), 156767 (rat)

Reactivity Mouse, Rat

Host Goat

Clonality Polyclonal Concentration 0.5 mg/ml

lsotype IgG

### TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Additional Information

#### **Other Names**

Tnfrsf1b; tumor necrosis factor receptor superfamily, member 1B; CD120b; TBPII; TNF-R-II; TNF-R75; TNFBR; TNFR1B; TNFR2; TNFR80; p75; p75TNFR; TNF-R2; TNF-RII; TNFR-II; p75 TNF receptor; p80 TNF-alpha receptor; soluble TNFR1B variant 1; tumor necrosis fac

### **Format**

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

#### **Precautions**

TNF-R-II / TNFR2 (mouse) Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

# TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Protein Information

# TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety



### • Cell Culture

# TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Images



AF3597a (0.2  $\mu$ g/ml) staining of Rat Spinal Cord lysate (35  $\mu$ g protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

## TNF-R-II / TNFR2 (mouse) Antibody (internal region) - Background

The immunizing peptide represents part of a potential extracellular domain.

## TNF-R-II / TNFR2 (mouse) Antibody (internal region) - References

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T. J Exp Clin Cancer Res. 2010 Jul 20;29:100. PMID: 20646319